Cargando…

Bicyclic Chalcones as Mitotic Inhibitors for Overcoming Androgen Receptor-Independent and Multidrug-Resistant Prostate Cancer

[Image: see text] To improve the biological effects of the lead compound 5′-chloro-2,2′-dihydroxychalcone (Cl-DHC), bicyclic aromatic chalcones were designed, synthesized, and evaluated against androgen-independent prostate cancer (PCa) DU145 and PC-3 cell proliferation. Newly synthesized bi-naphthy...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Yohei, Mizokami, Atsushi, Maeda, Sayaka, Takahashi, Kyoko, Izumi, Kouji, Goto, Masuo, Nakagawa-Goto, Kyoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905931/
https://www.ncbi.nlm.nih.gov/pubmed/33644592
http://dx.doi.org/10.1021/acsomega.0c05822
_version_ 1783655201643692032
author Saito, Yohei
Mizokami, Atsushi
Maeda, Sayaka
Takahashi, Kyoko
Izumi, Kouji
Goto, Masuo
Nakagawa-Goto, Kyoko
author_facet Saito, Yohei
Mizokami, Atsushi
Maeda, Sayaka
Takahashi, Kyoko
Izumi, Kouji
Goto, Masuo
Nakagawa-Goto, Kyoko
author_sort Saito, Yohei
collection PubMed
description [Image: see text] To improve the biological effects of the lead compound 5′-chloro-2,2′-dihydroxychalcone (Cl-DHC), bicyclic aromatic chalcones were designed, synthesized, and evaluated against androgen-independent prostate cancer (PCa) DU145 and PC-3 cell proliferation. Newly synthesized bi-naphthyl derivatives 2 and 3 suppressed the proliferation of these two cell lines and also taxane-resistant prostate cancer cell lines at a submicromolar level. The two compounds were 4–18 times more potent than the parent molecule Cl-DHC. A structure–activity relationship analysis revealed that the orientation of the 10π-electron ring-A naphthalene had a significant effect on the activity. Mode-of-action studies in KB-VIN cells demonstrated that 2 and 3 arrested cells in mitosis at prometaphase and metaphase followed by induction of sub-G1 accumulation. Thus, 2 and 3 have good potential as leads for continued development of treatments for cancers especially for not only androgen-independent PCa but also multidrug-resistant tumors.
format Online
Article
Text
id pubmed-7905931
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-79059312021-02-26 Bicyclic Chalcones as Mitotic Inhibitors for Overcoming Androgen Receptor-Independent and Multidrug-Resistant Prostate Cancer Saito, Yohei Mizokami, Atsushi Maeda, Sayaka Takahashi, Kyoko Izumi, Kouji Goto, Masuo Nakagawa-Goto, Kyoko ACS Omega [Image: see text] To improve the biological effects of the lead compound 5′-chloro-2,2′-dihydroxychalcone (Cl-DHC), bicyclic aromatic chalcones were designed, synthesized, and evaluated against androgen-independent prostate cancer (PCa) DU145 and PC-3 cell proliferation. Newly synthesized bi-naphthyl derivatives 2 and 3 suppressed the proliferation of these two cell lines and also taxane-resistant prostate cancer cell lines at a submicromolar level. The two compounds were 4–18 times more potent than the parent molecule Cl-DHC. A structure–activity relationship analysis revealed that the orientation of the 10π-electron ring-A naphthalene had a significant effect on the activity. Mode-of-action studies in KB-VIN cells demonstrated that 2 and 3 arrested cells in mitosis at prometaphase and metaphase followed by induction of sub-G1 accumulation. Thus, 2 and 3 have good potential as leads for continued development of treatments for cancers especially for not only androgen-independent PCa but also multidrug-resistant tumors. American Chemical Society 2021-02-09 /pmc/articles/PMC7905931/ /pubmed/33644592 http://dx.doi.org/10.1021/acsomega.0c05822 Text en © 2021 The Authors. Published by American Chemical Society Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Saito, Yohei
Mizokami, Atsushi
Maeda, Sayaka
Takahashi, Kyoko
Izumi, Kouji
Goto, Masuo
Nakagawa-Goto, Kyoko
Bicyclic Chalcones as Mitotic Inhibitors for Overcoming Androgen Receptor-Independent and Multidrug-Resistant Prostate Cancer
title Bicyclic Chalcones as Mitotic Inhibitors for Overcoming Androgen Receptor-Independent and Multidrug-Resistant Prostate Cancer
title_full Bicyclic Chalcones as Mitotic Inhibitors for Overcoming Androgen Receptor-Independent and Multidrug-Resistant Prostate Cancer
title_fullStr Bicyclic Chalcones as Mitotic Inhibitors for Overcoming Androgen Receptor-Independent and Multidrug-Resistant Prostate Cancer
title_full_unstemmed Bicyclic Chalcones as Mitotic Inhibitors for Overcoming Androgen Receptor-Independent and Multidrug-Resistant Prostate Cancer
title_short Bicyclic Chalcones as Mitotic Inhibitors for Overcoming Androgen Receptor-Independent and Multidrug-Resistant Prostate Cancer
title_sort bicyclic chalcones as mitotic inhibitors for overcoming androgen receptor-independent and multidrug-resistant prostate cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905931/
https://www.ncbi.nlm.nih.gov/pubmed/33644592
http://dx.doi.org/10.1021/acsomega.0c05822
work_keys_str_mv AT saitoyohei bicyclicchalconesasmitoticinhibitorsforovercomingandrogenreceptorindependentandmultidrugresistantprostatecancer
AT mizokamiatsushi bicyclicchalconesasmitoticinhibitorsforovercomingandrogenreceptorindependentandmultidrugresistantprostatecancer
AT maedasayaka bicyclicchalconesasmitoticinhibitorsforovercomingandrogenreceptorindependentandmultidrugresistantprostatecancer
AT takahashikyoko bicyclicchalconesasmitoticinhibitorsforovercomingandrogenreceptorindependentandmultidrugresistantprostatecancer
AT izumikouji bicyclicchalconesasmitoticinhibitorsforovercomingandrogenreceptorindependentandmultidrugresistantprostatecancer
AT gotomasuo bicyclicchalconesasmitoticinhibitorsforovercomingandrogenreceptorindependentandmultidrugresistantprostatecancer
AT nakagawagotokyoko bicyclicchalconesasmitoticinhibitorsforovercomingandrogenreceptorindependentandmultidrugresistantprostatecancer